Vimarsana
Biggest News Aggregation in the World

Page 30 - Ancer Immunotherapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ancer Immunotherapy Today - Breaking & Trending Today

FDA gives Gilead reprieve on partial hold for cancer drug studies - Vimarsana News

FDA gives Gilead reprieve on partial hold for cancer drug studies

An FDA safety review has cleared Gilead Sciences to resume five clinical trials that were placed under a partial hold in January. The experimental Gilead drug, magrolimab, is part of a class of cancer immunotherapies that address a hot target for the field.

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients - Vimarsana News

Adding immunotherapy to chemotherapy before surgery improves outcomes for NSCLC patients

Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC) — the leading cause of cancer deaths worldwide — reduced the risk of recurrence of the cancer or death by more than one-third, according to results from the phase III CheckMate-816 trial.

Werewolf cancer drug strikes right note with Jazz Pharma, sparking licensing deal - Vimarsana News

Werewolf cancer drug strikes right note with Jazz Pharma, sparking licensing deal

Jazz Pharmaceuticals is licensing rights to a Werewolf Therapeutics cytokine therapy that’s on track to reach clinical testing next year. The deal gives Jazz a drug candidate that expands the company’s scope to immuno-oncology.

Magneto-activated natural killer cells for treating solid tumors - Vimarsana News

Magneto-activated natural killer cells for treating solid tumors

Cancer immunotherapy-;a type of treatment that enlists our own immune cells to attack tumors-;has revolutionized the way that many types of cancer are treated. One type of immunotherapy under investigation uses natural killer cells, a type of immune cell that can seek and destroy harmful cells.

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target - Vimarsana News

Cell therapy biotech Affini-T gets $175M; KRAS is lead genomic cancer target

Affini-T Therapeutics is developing new cell therapies for cancer that could overcome limitations of the first generation of cell therapies. The initial genomic cancer targets of the startup are mutations of KRAS and p53, both of which have proven difficult to drug.